Arrowhead to Present at Jefferies 2015 Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead’s president and chief executive officer Christopher Anzalone, Ph.D., will present a corporate overview at the Jefferies 2015 Healthcare Conference on June 3, 2015 at 10:00 a.m. EDT.

Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page of the Company's website at http://ir.arrowheadresearch.com/events.cfm.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.

Source: Arrowhead Research Corporation

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005435/en/

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
[email protected]
or
Investor Relations:
The Trout Group
Todd James
646-378-2926
[email protected]
or
Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272
[email protected]

Source: Arrowhead Research Corporation

You May Also Be Interested In